Introduction: From ancient times, plants with medicinal values are being tested and used in treatment of various infectious disease.
Aims And Objectives: The presentin vitro study was designed to assess the antimicrobial activity of three commonly available medicinal plants Glycyrrhiza glabra, Ficus religiosa, and Plantago major on inhibiting Primary plaque colonizers and periodontal pathogens.
Materials And Methods: Bark of G. glabra, Stem of F. religiosa, and husk of P. major were collected, crushed into fine powder, and dissolved in 67% ethanol. Extracts were then subjected to test antimicrobial efficacy against primary plaque colonizers and periodontal pathogens using Kirby-Bauer disc diffusion method. Mean zone of inhibition (ZOI) was measured by HI antibiotic zone scale. One-way ANOVA using Tukey's post hoc and t-test were applied for statistical analysis.
Results: G. glabra was found to have potential antibacterial activity against primary plaque colonizers and periodontal pathogens with highest mean ZOI measuring 9.2 ± 1.09 mm and 10.6 ± 0.54 mm at 24 h, respectively. F. religiosa showed antibacterial activity against primary plaque colonizers only at 48 h with mean ZOI of 2.6 ± 0.54 mm. P. major showed no antibacterial activity against any of the microorganism in this study. Tukey's post hoc test showed statistically nonsignificant difference between G. glabra and standard antibiotic (vancomycin 10 mcg) for periodontal pathogens.
Conclusion: G. glabra and F. religiosa showed antibacterial activity against primary plaque colonizers and periodontal pathogens. However, further studies should be undertaken to affirm the same and test their efficacy in different concentration and clinical utility.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/0970-9290.183135 | DOI Listing |
Microorganisms
January 2025
Translational Neuropharmacology Laboratory, Department of Psychology, University of Cyprus, 75 Kallipoleos Avenue, 1678 Nicosia, Cyprus.
For decades, Alzheimer's Disease (AD) research has focused on the amyloid cascade hypothesis, which identifies amyloid-beta (Aβ) as the primary driver of the disease. However, the consistent failure of Aβ-targeted therapies to demonstrate efficacy, coupled with significant safety concerns, underscores the need to rethink our approach to AD treatment. Emerging evidence points to microbial infections as environmental factors in AD pathoetiology.
View Article and Find Full Text PDFDiagnostics (Basel)
January 2025
C2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA.
: The objective of this study was to assess clinical decision-making associated with the use of a multi-analyte blood biomarker (BBM) test among patients presenting with signs or symptoms of mild cognitive impairment or dementia. : The Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey (NCT06025877) study evaluated the clinical utility of the PrecivityAD2™ blood test in a prospective, single cohort of 203 patients presenting with symptoms of Alzheimer's disease (AD) or other causes of cognitive decline across 12 memory specialists. The PrecivityAD2 blood test (C2N Diagnostics, St.
View Article and Find Full Text PDFSci Rep
January 2025
Cardiology, Vascular Medicine and Pneumology, GRN Hospital Weinheim, Weinheim, Germany.
Agatston score, the degree of lumen narrowing categorized by CAD-RADS, high-risk atherosclerotic plaque features and pericoronary adipose tissue attenuation (PCAT) are parameters, which can be assessed non-invasively by coronary computed tomography angiography (CCTA) and aid risk stratification in patients with chronic coronary syndromes (CCS). However, few studies have so far compared the prognostic value of all those parameters together. To develop and test the prognostic value of a composite CCTA score, derived from Agatston score, CAD-RADS, high-risk plaques and PCAT in patients undergoing CCTA due to CCS.
View Article and Find Full Text PDFAnn Vasc Surg
January 2025
Division of Vascular and Endovascular Surgery, Mayo Clinic, Jacksonville, FL. Electronic address:
Introduction: Carotid artery stenosis is a significant contributor to ischemic strokes, and its surgical management includes carotid artery endarterectomy (CEA), transfemoral carotid artery stenting (TF-CAS), and trans carotid artery revascularization (TCAR). CEA has traditionally been preferred, but TF-CAS and TCAR are also excellent alternative options if the anatomy of the vessels allows them. This study reports our short- and mid-term outcomes after carotid artery revascularization in symptomatic patients at a stroke center.
View Article and Find Full Text PDFJ Clin Hypertens (Greenwich)
January 2025
Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
This first-in-man (FIM) study evaluated the feasibility and safety of a new peripheral plaque atherectomy system in patients with symptomatic lower extremity artery disease (LEAD). Ten patients with symptomatic LEAD (Rutherford class 2-5) were enrolled in a prospective, single-center study from March to April 2024. Patients aged 18-85 years with target lesions showing ≥70% stenosis and reference vessel diameters ≥1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!